Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scans could revolutionize how we see retinal disease

NCT ID NCT05355415

Knowledge-focused Sponsor: Food and Drug Administration (FDA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses special cameras to take ultra-detailed pictures of the back of the eye in people with retinal diseases like macular degeneration and retinitis pigmentosa. Researchers aim to develop new ways to diagnose and track these conditions by measuring cell density and function. The study will enroll 100 adults and involves no treatment—only imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better diagnostic tools and biomarkers for tracking retinal diseases, helping doctors detect changes earlier and monitor treatments more accurately.
What could go wrong
This is an observational imaging study, not a treatment trial. It is small (100 participants) and early-stage, so the findings may not apply to all patients or lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All study participants will be recruited from the NIH patient population.

Ages

21 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Are 21 years of age or older, 2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam), 3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and 4. Have been diagnosed with outer retinal disease or condition (Cohort 2). Exclusion Criteria: 1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity), 2. Have visual correction outside of the range +4 diopters (D) to -8 D, 3. Have a history of adverse reaction to mydriatic drops, 4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or 5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH/NEI AIs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration cone dystrophy cone-rod dystrophy late-onset retinal degeneration macular degeneration retinal degeneration retinitis pigmentosa toxic maculopathy due to antimalarial drugs Usher syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Cone dystrophy Cone-rod dystrophy Hydroxychloroquine retinopathy Late-onset retinal degeneration Retinal degeneration Retinitis pigmentosa Rod cone dystrophy Rod dystrophy Usher syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Food and Drug Administration

    RECRUITING

    Silver Spring, Maryland, 20993, United States

  • NIH Clinical Center

    RECRUITING

    Bethesda, Maryland, 20810, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.